p300 Modulates nuclear morphology in prostate cancerDEBES, Jose D; SEBO, Thomas J; HEEMERS, Hannelore V et al.Cancer research (Baltimore). 2005, Vol 65, Num 3, pp 708-712, issn 0008-5472, 5 p.Article

Peut-on prevenir le cancer de la prostate: Rôle de la nutritionZLOTTA, A. R; EKANE, S; SCHULMAN, C. C et al.Louvain médical. 2003, Vol 122, Num 2, pp S25-S33, issn 0024-6956Article

Traitement du cancer de la prostate hormono-résistantMACHIELS, J.-P.Louvain médical. 2003, Vol 122, Num 2, pp S68-S74, issn 0024-6956Article

Le diagnostic précoce du cancer de la prostateLORGE, F.Louvain médical. 2003, Vol 122, Num 2, pp S34-S43, issn 0024-6956Article

Xenoestrogen action in prostate cancer: Pleiotropic effects dependent on androgen receptor statusWETHERILL, Yelena B; FISHER, Nicola L; STAUBACH, Ann et al.Cancer research (Baltimore). 2005, Vol 65, Num 1, pp 54-65, issn 0008-5472, 12 p.Article

La radiothérapie dans les formes localisées du cancer de la prostateRENARD, L; VYNCKIER, S; SCALLIET, P et al.Louvain médical. 2003, Vol 122, Num 2, pp S50-S57, issn 0024-6956Article

Traitement du cancer de la prostate : Place de l'hormonothérapie en 2003TOMBAL, B; TAJEDDINE, N; VAN CANGH, P.-J et al.Louvain médical. 2003, Vol 122, Num 2, pp S58-S67, issn 0024-6956Article

Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasivenessGHOSH, Arundhati; XINNING WANG; KLEIN, Eric et al.Cancer research (Baltimore). 2005, Vol 65, Num 3, pp 727-731, issn 0008-5472, 5 p.Article

Confirmation of the HPCX prostate cancer predisposition locus in large Utah prostate cancer pedigreesFARNHAM, James M; CAMP, Nicola J; SWENSEN, Jeff et al.Human genetics. 2005, Vol 116, Num 3, pp 179-185, issn 0340-6717, 7 p.Article

Prostatectomie radicale : Traitement chirurgical du cancer prostatique localiséVAN CANGH, P.-J; TOMBAL, B; FEYAERTS, A et al.Louvain médical. 2003, Vol 122, Num 2, pp S44-S49, issn 0024-6956Article

Ukrain in the treatment of prostate cancer patientsB., Aschhoff.International journal of immunotherapy. 2003, Vol 19, Num 2-4, pp 41-45, issn 0255-9625, 5 p.Article

Genetic linkage of prostate cancer risk to the chromosome 3 region bearing FHITLARSON, Garry P; YAN DING; SLATER, Jerry et al.Cancer research (Baltimore). 2005, Vol 65, Num 3, pp 805-814, issn 0008-5472, 10 p.Article

Fiber optic SERS-based plasmonics nanobiosensing in single living cellsSCAFFIDI, Jonathan P; GREGAS, Molly K; SEEWALDT, Victoria et al.Proceedings of SPIE, the International Society for Optical Engineering. 2009, Vol 7312, issn 0277-786X, isbn 978-0-8194-7578-7 0-8194-7578-5, 731205.1-731205.8Conference Paper

Prostate cancer detection by laser induced autofluorescence and multicomponent spectroscopySALOMON, Georg; HESS, Thorsten; GRAEFEN, Markus et al.Proceedings of SPIE, the International Society for Optical Engineering. 2007, pp 67340H.1-67340H.8, issn 0277-786X, isbn 978-0-8194-6892-5, 1VolConference Paper

Prevention of hormone-related cancers: Prostate CancerPARNES, Howard L; THOMPSON, Ian M; FORD, Leslie G et al.Journal of clinical oncology. 2005, Vol 23, Num 2, pp 368-377, issn 0732-183X, 10 p.Article

Predictors of fatigue after treatment for prostate cancerMALISKI, Sally L; KWAN, Lorna; ORECKLIN, James R et al.Urology (Ridgewood, NJ). 2005, Vol 65, Num 1, pp 101-108, issn 0090-4295, 8 p.Article

Shared decision-making: Results from an interdisciplinary consulting service for prostate cancerSCHOSTAK, M; WIEGEL, T; MÜLLER, M et al.World journal of urology (Print). 2004, Vol 22, Num 6, pp 441-448, issn 0724-4983, 8 p.Article

Metafectene is superior to lipofectamine in the transfection of G₅α prostate cancer cellsICZKOWSKI, Kenneth A; OMARA-OPYENE, A. Levi; KLÖSEL, Roland et al.Molecular biotechnology. 2004, Vol 28, Num 2, pp 97-103, issn 1073-6085, 7 p.Article

Prostate cancerNELSON, William G; DE MARZO, Angelo M; ISAACS, William B et al.The New England journal of medicine. 2003, Vol 349, Num 4, pp 366-381, issn 0028-4793, 16 p.Article

Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progressionPRENSNER, John R; IYER, Matthew K; XUHONG CAO et al.Nature biotechnology (Print). 2011, Vol 29, Num 8, pp 742-749, issn 1087-0156, 8 p.Article

FTIR microspectroscopy for improved prostate cancer diagnosisMACKANOS, Mark A; CONTAG, Christopher H.Trends in biotechnology (Regular ed.). 2009, Vol 27, Num 12, pp 661-663, issn 0167-7799, 3 p.Article

Neuroendocrine differentiation in prostate cancer: Implications for newtreatment modalitiesVASHCHENKO, Nadezda; ABRAHAMSSON, Per-Anders.European urology. 2005, Vol 47, Num 2, pp 147-155, issn 0302-2838, 9 p.Article

Prostate cancerHORWICH, Alan; SULKES, Aaron; SCHRÖDER, Fritz H et al.Annals of oncology. 2006, Vol 17, issn 0923-7534, x199-x213, SUP10Conference Paper

Comparison of late rectal toxicity from conventional versus three-dimensional conformal radiotherapy for prostate cancer: Analysis of clinical and dosimetric factorsLEE, Christopher M; LEE, R. Jeffrey; HANDRAHAN, Diana L et al.Urology (Ridgewood, NJ). 2005, Vol 65, Num 1, pp 114-119, issn 0090-4295, 6 p.Article

Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasiaTAYEB, Mohammed T; CLARK, Caroline; HAITES, Neva E et al.Saudi medical journal. 2004, Vol 25, Num 4, pp 447-451, issn 0379-5284, 5 p.Article